Aurobindo Pharma Ltd’s consolidated net profit increased 5.7 per cent to Rs 235 crore in the second quarter ended September 30, 2013, compared with Rs 222 crore in the year-ago period.
Its scrip zoomed 9.27 per cent on the BSE on Friday to end at Rs 260.45.
The Hyderabad-based company’s total income grew 27.6 per cent to Rs 1,913 crore (Rs 1,500 crore), driven by over 30 per cent growth in formulations sale and growth in the active pharmaceuticals ingredients segment.
Revenue from the formulations segment in the US increased 72 per cent to Rs 730 crore.
“The integrated business in generic formulations is auguring well to drive the operating performance of the company. We are also investing in specific new, differentiated products offerings such as Oncology, Hormones, Peptides and OTC (over the counter) business, which we believe will complement our business in the coming years," N. Govindarajan, Managing Director, said in a release.
The board of directors at its meeting held on Thursday had approved payment of an interim dividend of 125 per cent (Rs 1.25) per equity share of Re 1 each for the financial year 2013-14. It would be paid on or after November 27.